Ticker brief
ERAS ERASCA INC
Consumer, Non-cyclical · Biotechnology
last close
$14.39
1 day
+2.5%
14 days
-10.2%
mkt cap
$5.7B
signals 14d
18
authors 14d
7
crowd 14d
+0.9σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 106% | IV/HV 1.50× (as of 2026-10-22) |
| Skew — 25Δ RR 30d | +0.016 | 25Δ call IV − put IV |
| Net dealer OI (NDOI) | +2.45 elevated | 5-session Δ +0.50 (as of 2026-07-09) |
| OI alarm | quiet | last alarm 2026-06-30 (z=7.2) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-15 · now +0.25 (−1 bearish … +1 bullish)
Who spoke7
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.87 | 10 | +0.56 |
| @Pharmdca | C | -3.41 | 2 | +0.55 |
| @zohmbastic | C | -2.94 | 2 | +0.13 |
| @3PeaksTrading | B | -1.72 | 1 | +0.35 |
| @Brad_E_Schulz | C | · | 1 | +0.35 |
| @Options | C | · | 1 | +0.00 |
| @equitydd | C | -1.08 | 1 | +0.10 |
Recent signals18of 18 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @bioinvestor24 | +0.15 | Compares oncology response and toxicity data, praising VSTM efficacy while flagging vomiting and liver-enzyme risks. | -3.2% | tweet ↗ |
| 2026-10-15 | @bioinvestor24 | +0.35 | Compares upcoming pan-RAS datasets and says response durability will determine competitive positioning. | -3.2% | tweet ↗ |
| 2026-10-13 | @bioinvestor24 | +0.70 | Add to small biotech positions as pressure shifts toward big pharma. — Explicitly calls the setup an opportunity to add to small positions after contrasting biotech assets with big pharma. | -2.6% | tweet ↗ |
| 2026-10-11 | @equitydd | +0.10 | Lists the first six stocks in a broad ranking of currently trending names. | -10.2% | tweet ↗ |
| 2026-10-11 | @bioinvestor24 | +0.50 | Contrasts RVMD's mutation limitations with a potentially complementary ERAS inhibitor combination. | -10.2% | tweet ↗ |
| 2026-10-10 | @bioinvestor24 | +0.45 | Sees cracks in RVMD's thesis versus ERAS while contrasting Nvidia's product lead with AMD. | -10.2% | tweet ↗ |
| 2026-10-08 | @Options | +0.00 | Podcast summary notes AI-stock losses and unusual options flow in three other names. | -6.9% | tweet ↗ |
| 2026-10-08 | @Brad_E_Schulz | +0.35 | Lists high-volume gainers; output capped at the first six tickers. | -6.9% | tweet ↗ |
| 2026-10-08 | @bioinvestor24 | +0.40 | Argues pan-RAS breadth and response duration may favor ERAS in forthcoming comparative data. | -6.9% | tweet ↗ |
| 2026-10-08 | @zohmbastic | +0.15 | Characterizes ERAS's end-of-day action as decent. | -6.9% | tweet ↗ |
| 2026-10-08 | @bioinvestor24 | +0.50 | Sets a 35–40% response-rate threshold that would support ERAS potency. | -6.9% | tweet ↗ |
| 2026-10-08 | @bioinvestor24 | +0.80 | Says strong ERAS data versus RVMD's 24% response rate could cause a massive rerating. | -6.9% | tweet ↗ |
| 2026-10-08 | @Pharmdca | +0.35 | Notes ERAS trading positively while the broader market is down. | -6.9% | tweet ↗ |
| 2026-10-08 | @bioinvestor24 | +0.90 | Calls ERAS and VKTX best-in-class and predicts eventual sharp upside. | -6.9% | tweet ↗ |
| 2026-10-08 | @bioinvestor24 | +0.90 | Speculates ERAS has strong data or M&A interest and predicts multiple-fold upside. | -6.9% | tweet ↗ |
| 2026-10-08 | @3PeaksTrading | +0.35 | ERAS rose 7% with recent call buying in open interest before next month's drug data. | -6.9% | tweet ↗ |
| 2026-10-08 | @zohmbastic | +0.10 | Flags a block trade in ERAS during today's session. | -6.9% | tweet ↗ |
| 2026-10-06 | @Pharmdca | +0.75 | Adding to existing positions in INBX, ERAS, KURA, TNGX and BBIO. — Explicitly reports current additions to five biotech positions. | +0.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.